0.00Open0.04Pre Close0 Volume957 Open Interest8.00Strike Price0.00Turnover2155.44%IV6.21%PremiumDec 6, 2024Expiry Date0.00Intrinsic Value100Multiplier-4DDays to Expiry0.04Extrinsic Value100Contract SizeAmericanOptions Type0.5197Delta3.3465Gamma189.25Leverage Ratio-140.1459Theta0.0000Rho98.35Eff Leverage0.0000Vega
Recursion Pharmaceuticals Stock Discussion
Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class Cdk7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability
No comment yet